Tech-Enabled Services
Seeking to help companies leverage advanced technologies and enhance patient outcomes through better monitoring, data analysis, and personalized treatment options.
Growth potential
Largest segment of healthcare sector
Aging population
HCIT advancements
Shift toward big data/predictive analysis
Decreased fee-for-service options
Improved AI/ML and interoperability
More outsourcing/partnership models
Rising consumer demand and awareness
Move toward personalized remote care
Secure healthcare data exchanges
Growth potential
- Largest segment of healthcare sector
- Aging population
- HCIT advancements
- Shift toward big data/predictive analysis
- Decreased fee-for-service options
- Improved AI/ML and interoperability
- More outsourcing/partnership models
- Rising consumer demand and awareness
- Move toward personalized remote care
- Secure healthcare data exchanges
Tech-Enabled Services Companies
We are actively focused on identifying potential diagnostics opportunities we believe serve critical roles in reducing costs to the healthcare system and improving outcomes for patients through earlier diagnosis of disease and personalized treatment recommendations.
EW has identified several subsectors we believe are growth equity opportunities:
- Diagnostics
- Proprietary Lab Services
- Contract Manufacturing, Development and Research Organizations (CMO/CDMOs & CROs)
- Specialized Pharma Services
- Combination Device/Service Models
- Life Science Tools
Common questions
How can healthcare tech-enabled services improve patient care?
Tech-enabled services play a pivotal role in enhancing patient care and outcomes by enabling early disease detection, personalized treatment plans, quicker and accurate diagnostics, streamlined drug development, improved treatment adherence, real-time health monitoring, and advanced research capabilities. These innovations collectively optimize healthcare processes, leading to more precise, efficient, and patient-centered care.
How has the COVID-19 pandemic influenced tech-enabled healthcare services?
The COVID-19 pandemic has significantly accelerated investment in tech-enabled healthcare services. Telemedicine platforms, remote patient monitoring, and digital health solutions experienced a surge in adoption as healthcare providers sought ways to deliver care while minimizing physical contact.
What are the emerging areas of tech-enabled services?
The emerging areas of tech-enabled services identified by EW Healthcare Partners include diagnostics, proprietary lab services, contract manufacturing, development, and research organizations (CMO/CDMOs & CROs), specialized pharma services, combination device/service models, and life science tools. These sectors leverage technology to enhance healthcare operations, improve patient outcomes, and streamline processes.
What role does cybersecurity play in tech-enabled services?
In the realm of tech-enabled services, cybersecurity plays a crucial role in safeguarding sensitive patient data and ensuring the secure transmission of medical information. As healthcare services increasingly rely on technology and data exchange, robust cybersecurity measures are essential to protect patient privacy, prevent data breaches, and maintain the integrity of medical records and systems.
How does the regulatory environment affect tech-enabled services?
The regulatory environment significantly influences tech-enabled services within the healthcare sector. Companies operating in these sectors must navigate complex regulations and compliance standards to ensure patient safety, data privacy, and quality assurance. Stricter regulations such as HIPAA in the United States and GDPR in Europe impact how patient data is collected, stored, and shared. Adhering to these regulations is essential for maintaining ethical standards and avoiding legal penalties.
Ryan Marcotte
“Enercon is excited to partner with EW Healthcare for the next stage of our company’s growth,” said Ryan Marcotte, CEO at Enercon Technologies. “EW enhances Enercon’s already strong financial and operational position by providing expertise in Enercon’s core end markets of Healthcare and MedTech. EW shares our vision of growing Enercon as a platform and they align with our values and culture that our employees are our most important asset. We are thrilled to have EW as our partner.”
Tony Koblish
“I have worked across two companies with EW as largest shareholder with great success. EW offers tremendous depth, experience, and passion for building top-shelf MedTech companies that help surgeons help patients. EW partners with management in a truly value added collaboration process with competency and mutual respect. I consider EW a top investment partner.”
Peter Van Haur
“EW has become a trusted partner as we work to grow the VitalConnect business. The expertise, insights and extensive relationships they have brought have been instrumental across multiple aspects of diligence, commercialization and funding which has allowed us to grow shareholder value together.”
Ted Davis
“The EW team has been a terrific partner for us at BioTissue. In addition to EW’s expertise and commitment to the regenerative medicine space, the firm has an intentional approach of bringing specific skill sets to each portfolio company. EW’s Board representation includes operating perspective and financial/investment expertise, which provides a robust foundation for our Board as we drive our strategic transformation at BioTissue. Shaunak and Bob have been great partners for our Founders, our co-investors and our management team, willing to simply weigh in as a sounding board or “roll up their sleeves” when needed.”
Joseph Capper
“EW Healthcare has been a trusted partner of ours for several years, and we appreciate their support in working toward a shared vision of patient-centered innovation in healthcare. In my time as CEO at MIMEDX, the team at EW has offered valuable strategic counsel at the board level and contributed meaningfully to our growth story.”
Morris Miller
“We are thrilled to partner with EW. With their understanding of the medical device space and how companies should operate, EW has added value from ‘Day 1’. We were very impressed with the careful diligence conducted by the EW team, and we look forward to a great future together!”
Nancy Lurker
“I am so pleased with our working relationship and the experience, guidance and support that EW provides to EyePoint Pharmaceuticals. The quality of their input, at both the Board level and the management level, has been superb and we have forged a true partnership.”
Karen Zaderej
“The EW team is extremely knowledgeable, and their ability to identify great innovations and market opportunities, and help move those innovations forward by sharing expertise and assisting in business plan execution is remarkable. AxoGen is proud to have Essex as a partner in our continued growth.”
Bryan Morton
“EW Healthcare Partners is not so much an Investor as a Partner in building successful businesses as was my experience with EUSA.”
Testimonials and endorsements reflect portfolio company management’s opinions and beliefs regarding the company and the investment. Such opinions and beliefs are subjective, do not represent a complete assessment of the company, the market or EW’s overall investment performance and cannot be independently verified. Such statements are being offered as references for purposes of demonstrating the benefits of working with the EW team and not for the purpose of soliciting investors. Portfolio company executives receive/received a salary and economics from the portfolio company. No executives were paid for their testimonial or endorsement. There is a conflict of interest in these unpaid testimonials and endorsements in that all speakers stand to benefit from EW’s success and they work/worked for an EW portfolio company.